Telix wins FDA Fast Track for BiPASS pre-biopsy prostate cancer imaging study

Bitget2026/09/29 22:31

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Telix received FDA Fast Track designation for BiPASS, a Phase 3 program testing 68Ga PSMA-PET with MRI before prostate biopsy.
Enrollment in the Phase 3 study is complete; no trial results were reported in the announcement.
Fast Track increases FDA interaction, potentially supporting an accelerated review timetable for a planned NDA submission.
The program targets earlier diagnosis, aiming to reduce unnecessary biopsies while improving identification of clinically significant prostate cancer.
Illuccix and Gozellix remain investigational for pre-biopsy use despite existing approvals in other prostate cancer imaging settings.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Telix Pharmaceuticals Ltd. published the original content used to generate this news brief on September 30, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Telix wins FDA Fast Track for BiPASS pre-biopsy prostate cancer imaging study

You may also like

Crypto prices